MTOR and breast neoplasm: Given the demonstrated efficacy of Gedatolisib against quiescent breast tumor cells in organotypic culture, we designed a preclinical study to (a) determine whether PI3K/mTOR is a critical node downstream of integrin‐β1 in vivo and (b) coincide with the GLACIER trial to determine the predictive capacity of these preclinical models.